Vertex Pharmaceuticals Incorporated
CTX001
Beta-Thalassemia
Countdown
334days
Phase 3 readout · Jun 6, 2027
What's at stake
Phase 3 trial results for CTX001 in Beta-Thalassemia are due Jun 6, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT05329649: Phase 3 trial, sponsor Vertex Pharmaceuticals Incorporated, drug CTX001. Primary completion date 2027-06-06 (estimated).”